Jun 13, 2026
Jun 13, 2026
Jun 13, 2026
Jun 13, 2026
Jun 13, 2026
Jun 13, 2026
Jun 13, 2026
Jun 13, 2026
CRISPR Therapeutics, backed by a solid $2.4 billion liquidity, struggles with stock movement despite a $2.2 million gene-editing therapy launch. What's holding it back?